Last-Resort leukemia drug made available to patients who have run out of options
Disease control
TEMPORARILY_NOT_AVAILABLE
This program gives access to vodobatinib for people with Philadelphia chromosome-positive chronic myeloid leukemia (CML) whose cancer has not responded to previous treatments. It is for patients who still benefit from the drug and have no other treatment choices. The goal is to k…
Sponsor: Sun Pharma Advanced Research Company Limited • Aim: Disease control
Last updated May 11, 2026 20:47 UTC